1. Collins, P. Clinical cardiovascular studies of hormone replacement therapy. Am. J. Cardiol. 90, 30F–34F (2002).
2. Ren, J. & Kelley, R. O. Cardiac health in women with metabolic syndrome: clinical aspects and pathophysiology. Obesity (Silver Spring) 17, 1114–1123 (2009).
3. Skafar, D. F., Xu, R., Morales, J., Ram, J. & Sowers, J. R. Clinical review 91: female sex hormones and cardiovascular disease in women. J. Clin. Endocrinol. Metab. 82, 3913–3918 (1997). This review addresses potential mechanisms by which oestrogen and progesterone exert their cardiovascular protective effects such as genomic and non-genomic effects.
4. Yanes, L. L. & Reckelhoff, J. F. Postmenopausal hypertension. Am. J. Hypertens. 24, 740–749 (2011).
5. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. WHO http://www.who.int/cardiovascular_diseases/publications/Prevention_of_Cardiovascular_Disease/en/ (2007). This document provides guidance on reducing disability and premature death from CVD, through changes in lifestyle and prophylactic drug therapies, in people at high risk but who have not yet experienced a cardiovascular event.